Switch View
© BusinessWire
20.08.2025
ISIN: US6556631025
Nordson Corp
NDSN
LISTED
NASDAQ
Nordson EFD Completes Eighth Job Shadowing Program with Polaris MEP
News Preview
Nordson EFD, a Nordson company (NASDAQ: NDSN), announced today it has completed its eighth year of support for the "Fast Track to Advanced Manufacturing" job shadowing program. Hosted by Polaris MEP and the Community College of Rhode Island (CCRI), this is a community-based program in its second year of support for the Jane Addams Resource Corpora...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Transaction in Own Shares
News Preview
For immediate release20 August 2025WORLDWIDE HEALTHCARE TRUST PLC(the "Company")MARKET PURCHASE OF COMPANY'S OWN SHARESThis notification is given, pursuant to the authority granted at an Annual General Meeting of the Company held on 9 July 2025 to make market purchases of the Company's own shares up to an aggregate maximum of 69,602,221.The Compa...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: GB00BN4HT335
Indivior PLC
INDV
LISTED
NASDAQ
Indivior to Participate in Upcoming Investor Events
News Preview
RICHMOND, Va., Aug. 20, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ: INDV) today announced that it will participate in the following investor events:
Morgan Stanley 23rd Annual Global Healthcare Conference – New York City, NYJoe Ciaf...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
20.08.2025
ISIN: CA58469E4085
Medicure Inc.
MPH
LISTED
TSX
Medicure Reports Financial Results for Quarter Ended June 30, 2025
News Preview
WINNIPEG, MB / ACCESS Newswire / August 20, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the q...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
20.08.2025
ISIN: IE000LK2BOB4
Mural Oncology PLC
MURA
LISTED
NASDAQ
MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mural Oncology plc (NASDAQ: MURA) to XOMA Royalty Corporation for $2.035 per share and, up to an additional $0.205 per share under certain conditions, is fair to Mural shareholders.
Halper Sadeh encourages Mural shareholders to click here to learn more about thei...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.08.2025
ISIN: NL0010391025
Pharming Group NV
PHARM
LISTED
EURONEXT
First Berlin Equity Research GmbH: Pharming Group NV | Rating: Buy
News Preview
Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
20.08.2025 / 16:37 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude ......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.08.2025
ISIN: DE000A3CMGM5
Apontis Pharma AG
APPH
LISTED
XETR
Changes in the management board
News Preview
APONTIS PHARMA: Changes in the management board
Monheim am Rhein, 20 August 2025. Bruno Wohlschlegel, CEO of APONTIS PHARMA AG (ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company for single-pill combinations in Germany, is to leave the company at the end of August 2025 with the end of his contract. Wohlschlegel will take on an advis......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.08.2025
ISIN: DE000A3CMGM5
Apontis Pharma AG
APPH
LISTED
XETR
Veränderungen im Vorstand
News Preview
APONTIS PHARMA: Veränderungen im Vorstand
Monheim am Rhein, 20. August 2025. Der Vorstandsvorsitzende der APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), einem führenden Pharmaunternehmen für Single Pill-Kombinationen in Deutschland, wird das Unternehmen nach Ablauf seines Vertrages Ende August 2025 verlassen. Bruno Wohlschlegel wird bis Ende ......
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
News Preview
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates to the fourth quarter of 2025 for two EYLEA HD® (aflibercept) Injection 8 mg regulatory submissions. This includes a Chemistry, Manufacturing and Co...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ISIN: US71715X2036
PharmaCyte Biotech, Inc.
PMCB
LISTED
NASDAQ
PharmaCyte Biotech, Inc. Announces Closing of $7 Million Financing
News Preview
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing.
As of April 30, 2025, PharmaCyte had approximately $15.5 million in cash and also holds over $30 million of securities as reflected in the Company’s most recent 10K. With the addition of the $7 mil...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: US7574683014
Redhill Biopharma Ltd
RDHL
LISTED
NASDAQ
RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
News Preview
The New York Supreme Court has awarded RedHill approximately $1.82 million in legal costs and expenses following, and in addition to, the Court's prior summary judgment of approximately $8.25 million in favor of RedHill in its action against Kukbo Co. Ltd's ("Kukbo"); the $8.25 million and $1.82 million awards include 9% ongoing statutory interes...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
20.08.2025
ISIN: US5324571083
Eli Lilly and Co
LLY
LISTED
NYSE
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
News Preview
INDIANAPOLIS, Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her r...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLCLEI: 5493003YBCY4W1IMJU04NET ASSET VALUEThe estimated un-audited net asset value per share, calculated in accordance with the guidelines of the Association of Investment Companies, for Worldwide Healthcare Trust PLC at the close of business on 19 August 2025 was 347.94p (cum income). ...
Themefolio
Profiler
Peergroup
© Newsfile
20.08.2025
ISIN: CA75671E1097
Red Light Holland Corp.
TRIP
LISTED
CSE
Red Light Holland Applauds HHS Review of Psilocybin Rescheduling Petition, Expresses Optimism for Reversal of Schedule I Classification
News Preview
Toronto, Ontario--(Newsfile Corp. - August 20, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of magic truffles t...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: US03528H1095
Anixa Biosciences, Inc.
ANIX
LISTED
NASDAQ
Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
News Preview
Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine
Expands global intellectual property coverage in markets with high breast cancer incidence
New patent will provide IP protection of Breast Cancer Vaccine in China into at least the 2040s
SAN JOSE, Calif., Aug. 20, 2025 /PRNewswire/ -- Anixa Biosciences, Inc...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: CA40390B1094
HLS Therapeutics Inc
HLS
LISTED
TSX
HLS Therapeutics Announces New Credit Agreement
News Preview
CAD $79 million term loan replaces USD $56 million term loanCAD $107 million (~USD $77.5 million) total facility provides enhanced financial flexibility CAD-denominated facility reduces FX exposure and lowers interest rate TORONTO, Aug. 20, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing o...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: US04962H2094
Atossa Therapeutics, Inc.
ATOS
LISTED
NASDAQ
Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer
News Preview
Monotherapy Phase 2 study designed with FDA input; IND expected in Q4 2025
Topline results anticipated in 2026
Positions Atossa for transition into registrational Phase 3 development
SEATTLE, Aug. 20, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing i...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: US8989201038
TuHURA Biosciences, Inc.
HURA
LISTED
NASDAQ
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
News Preview
TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025...
Themefolio
Profiler
Peergroup
© Newsfile
20.08.2025
ISIN: US29415V1098
Envoy Medical, Inc.
COCH
LISTED
NASDAQ
Envoy Medical Secures Three New Patents, Strengthening Leadership in Fully Implantable Hearing Technology
News Preview
Patents issued in the U.S., Australia, and Hong Kong advance Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss.White Bear Lake, Minnesota--(Newsfile Corp. - August 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ISIN: US00846U1016
Agilent Technologies Inc
A
LISTED
NYSE
Agilent MMR IHC Panel pharmDx (Dako Omnis) Receives FDA Approval as a Companion Diagnostic Test for Colorectal Cancer
News Preview
Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received FDA approval as a companion diagnostic (CDx) test for colorectal cancer. This test aids in identifying mismatch repair deficient (dMMR) colorectal cancer (CRC) patients who are eligible for treatment with Bristol Myers Squibb’s Opdivo® (niv...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ISIN: US04963C2098
AtriCure Inc
ATRC
LISTED
NASDAQ
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
News Preview
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2025 Wells Fargo Healthcare Conference.
AtriCure’s management is scheduled to pa...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ISIN: US30052C1071
Evolus Inc
EOLS
LISTED
NASDAQ
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US4923271013
Keros Therapeutics Inc
KROS
LISTED
NASDAQ
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
News Preview
LEXINGTON, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”)...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: DK0062498333
Novo Nordisk A/S
NOVO B
LISTED
CPH
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
News Preview
Bagsværd, Denmark, 20 August 2025 – Novo Nordisk today announced new data showing the cardiovascular protective benefits of Wegovy® and Ozempic® will be presented at the European Society of Cardiology (ESC) Congress 2025 from 29 August to 1 September in Madrid, Spain. New data will also include perspectives on the role of inflammation in a conditio...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: IE00B4Q5ZN47
Jazz Pharmaceuticals PLC
JAZZ
LISTED
NASDAQ
Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355
News Preview
Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales
Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications
For U.S. media and investors only
DUBLIN and COPENHA...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: IE00BGH1M568
Perrigo Company PLC
PRGO
LISTED
NYSE
Perrigo to Attend Barclays 18th Annual Global Consumer Staples Conference
News Preview
DUBLIN, Aug. 20, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to participate in one-on-one investor meetings at the Barclays Global Consumer Staples Conference on Wednesday, September 3r...
Themefolio
Profiler
Peergroup
© Newsfile
20.08.2025
ISIN: CA68405H1001
Optimi Health Corp
OPTI
LISTED
CSE
Optimi Health Provides Corporate Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a manufacturer of GMP-certified MDMA and psilocybin, is pleased to announce it has entered into an agreement with MZ Investor Relations ("MZ"), an investor relations firm. MZ will provide Optimi wi...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US3207031010
Calidi Biotherapeutics, Inc.
CLDI
LISTED
XASE
Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
News Preview
SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the pricing of an underwritten public offer...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: US23283X2062
Cytosorbents Corp
CTSO
LISTED
NASDAQ
CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR
News Preview
FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization
PRINCETON, N.J., Aug. 20, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac s...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US31447E1055
Femasys Inc
FEMY
LISTED
NASDAQ
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
News Preview
--Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced that it received the Medicines and Healthcare...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US9026731029
UFP Technologies Inc
UFPT
LISTED
NASDAQ
UFP Technologies to Present and Host 1x1 Investor Meetings at the 16th Annual Midwest IDEAS Investor Conference on August 26th in Chicago, IL
News Preview
NEWBURYPORT, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (UFPT), today announced Mitch Rock, President, and Ron Lataille, Sr. VP and CFO, will present at the Midwest IDEAS Investor Conference on Tuesday, August 26, 2025, at The InterContinental in Chicago, IL. UFP’s presentation is scheduled to begin at 7:55 AM CT. The present...
Themefolio
Profiler
Peergroup
© Newsfile
20.08.2025
ISIN: CA74141E1043
PreveCeutical Medical Inc.
PREV
LISTED
CSE
BioGene Therapeutics Inc. Appoints Dr. Francis Tavares, PhD., as Chief Technology Officer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
News Preview
Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer.
This submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitan...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ISIN: US29251M1062
Enanta Pharmaceuticals Inc
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 3507...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US98419J2069
XOMA Royalty Corp
XOMA
LISTED
NASDAQ
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
News Preview
WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“XOMA Royalty”), announced today they have entered into a definitive agreement pursuant to which...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US00688A2050
Adial Pharmaceuticals Inc
ADIL
LISTED
NASDAQ
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
News Preview
U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory Environment U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory Environment...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US01626L1052
Aligos Therapeutics, Inc.
ALGS
LISTED
NASDAQ
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Ramón Polo, PharmD, PhD, MBA as Senior Vice President, Head of Glo...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US59503A2042
Microbot Medical Inc.
MBOT
LISTED
NASDAQ
Microbot Medical® Granted U.S. Patent that Significantly Expands Potential Market Applications
News Preview
With the Newly Granted IP, the Company’s IP Portfolio for the LIBERTY® System now includes 12 patents granted globally and 57 patent applications pending....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US92854B1098
Vivani Medical, Inc.
VANI
LISTED
NASDAQ
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
News Preview
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwrigh...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: IE000LK2BOB4
Mural Oncology PLC
MURA
LISTED
NASDAQ
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
News Preview
WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company (“Mural”), and XOMA Royalty Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator (“XOMA Royalty”), announced today they have entered into a definitive agreement pursuant to...
Themefolio
Profiler
Peergroup
© Newsfile
20.08.2025
ISIN: CA9255401064
Vext Science, Inc.
VEXT
LISTED
CSE
Vext Announces Q2 2025 Financial Results: Record Quarterly Revenue with Strong 31% Cash Flow Margin
News Preview
Record financial performance, with growth in revenue, adjusted EBITDA, and operating cash flow driven by strong Ohio momentum and disciplined operations in Arizona.Revenue of $13.4 million, up 59% YoY and a sequential increase of $1.8 million, reflecting first full quarter of consolidation of Big Perm dispensaries.Adjusted EBITDA[1] of $4.1 million...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2025
ISIN: KYG9TY5A1016
Zura Bio Ltd
ZURA
LISTED
NASDAQ
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
News Preview
Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: IE00BF3W0Q35
Iterum Therapeutics Plc
ITRM
LISTED
NASDAQ
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
News Preview
FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US1079241022
BridgeBio Oncology Therapeutics, Inc.
BBOT
LISTED
NASDAQ
BBOT to Participate in Upcoming September Investor Healthcare Conferences
News Preview
BBOT to Participate in Upcoming September Investor Healthcare Conferences...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US00091E1091
Absci Corp
ABSI
LISTED
NASDAQ
Absci to Participate in Upcoming Investor Conferences
News Preview
VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. to Present at the Wells Fargo 2025 Healthcare Conference
News Preview
MINNEAPOLIS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 2025 Heal...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US71722W1071
Phathom Pharmaceuticals Inc
PHAT
LISTED
NASDAQ
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
News Preview
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrative changes to its reporting approach but does not represent a reduction in the ownership position of...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Names Jim Daly to Board of Directors
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: IL0011316309
Mediwound Ltd
MDWD
LISTED
NASDAQ
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference
News Preview
YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: CA4990531069
Knight Therapeutics Inc
GUD
LISTED
TSX
Knight Announces Normal Course Issuer Bid
News Preview
MONTREAL, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"), a pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the "TSX") of the Company's Notice of Intention to Make a Normal Course Issuer Bid ("NCIB"). Pursuant to the NCIB, the Compan...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US76200L3096
Rezolute, Inc.
RZLT
LISTED
NASDAQ
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
News Preview
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US0327973006
Anavex Life Sciences Corp
AVXL
LISTED
NASDAQ
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease
News Preview
Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: US44975P1030
I-Mab
IMAB
LISTED
NASDAQ
I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update
News Preview
ROCKVILLE, Md., Aug. 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced financial results for the three and six months ended June 30, 2025, and highlighted recent pipeline progres...
Themefolio
Profiler
Peergroup
© PR Newswire
20.08.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1/CTLA-4) for Perioperative Treatment of Resectable Gastric Cancer
News Preview
HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso, in combination with chemotherapy for the p...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
News Preview
REYKJAVIK, ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Patrik Ling has joined the company as VP Investor Relations Scandinavia, based in Stockholm....
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.08.2025
ISIN: US9495031067
Wellgistics Health, Inc.
WGRX
LISTED
NASDAQ
Wellgistics Health Achieves Stability in First-Half 2025 and Executes Growth Initiatives
News Preview
TAMPA, FLORIDA / ACCESS Newswire / August 20, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced financial results for the second fiscal quarter ended June 30,...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.08.2025
ISIN: US4327053090
Tharimmune Inc
THAR
LISTED
NASDAQ
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
News Preview
RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and unmet medical needs announced positive results from a recent pharmacokinetic (PK) si...
Themefolio
Profiler
Peergroup
© Newsfile
20.08.2025
ISIN: CH1176493729
Bachem Holding AG
BANB
LISTED
SIX
Bachem Expands Corporate Executive Committee to Include Chief Operations Officer Role
News Preview
Bubendorf, Switzerland--(Newsfile Corp. - August 20, 2025) - The Bachem Group (SIX: BANB) announced today that Hans Van Hees, currently Chief Operations Officer Europe, will take on the role of Chief Operations Officer (COO) and join the Corporate Executive Committee (CEC) as of September 1, 2025. In this role, he will report to the CEO...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.08.2025
ISIN: US29415J1060
enVVeno Medical Corporation
NVNO
LISTED
NASDAQ
enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)
News Preview
IRVINE, CA / ACCESS Newswire / August 20, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received a not-approvable letter from the U.S. Food & Drug Administration (FDA) in response to...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
